Breakthrough Test Treats Patients with Colorectal Cancer

Prescient Metabiomics has launched a new non-invasive colorectal cancer diagnostic test, LifeKit® Prevent Colorectal Neoplasia designed to deploy patented metagenomics technologies.

The test also identifies microbial DNA and RNA biomarkers associated with the new abnormal growth of tissue in the gastrointestinal tract.

The test can identify patients with pre-cancerous polyps and early-stage carcinomas, and help identification of carcinogenesis and prevention of Colorectal Cancer (CRC) resulting in more people getting treated before the disease progresses.

The LifeKit Prevent offers more accurate detection of colon cancer and precancerous adenomas that are undetected by the existing non-invasive tests.

The positive results from the analysis of microbial biomarkers in the stool are collected using a non-invasive collection swab, which indicated the presence of colorectal adenomas or CRC, followed by appropriate diagnostic colonoscopy and polypectomy tests.

The US Food and Drug Administration has given its breakthrough designation for the Colorectal Test.

Latest Issue
Get instant
access to our latest e-book
Sanofi UpperEdge - Healthcare ERP Transformation Medical Manufacturing Asia 2022 Medical Fair Asia 2022